Hospital
North Arkansas Regional Medical Center
North Arkansas Regional Medical Center was paid $7.95M by Medicaid between Jan 2018 and Dec 2024, across 200 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 9.5% of everything it billed.
33Billing provider infoNORTH ARKANSAS REGIONAL MEDICAL CENTER
HARRISON, AR 72601
HARRISON, AR 72601
33aNPI1275523912assigned 10/25/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.95M
24GClaims416,741
24DCodes billed200
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#12 of 49
Median peer was paid$2.62M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, ANDREA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 70,302 | $933K | |
| 2019 | 69,375 | $1.28M | |
| 2020 | 53,791 | $1.05M | |
| 2021 | 51,561 | $1000K | |
| 2022 | 53,804 | $1.20M | |
| 2023 | 66,347 | $1.36M | |
| 2024incomplete | 51,561 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.5% | 22,444 | 5,021 | $759K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 7.2% | 5,838 | 5,046 | $574K |
| A0425 | Ground mileage, per statute mile | 5.6% | 6,494 | 4,289 | $442K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 4.9% | 1,240 | 1,045 | $386K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,737 | 2,376 | $374K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 3,696 | 3,252 | $349K |
| 80053 | Comprehensive metabolic panel | 4.2% | 22,843 | 18,305 | $336K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.9% | 820 | 722 | $233K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 4,743 | 3,708 | $204K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 3,420 | 2,086 | $204K |
| 80050 | General health panel | 2.4% | 4,981 | 2,274 | $187K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 26,177 | 20,355 | $180K |
188 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.2% | 5,017 | $178K |
| 87503 | 1.8% | 5,835 | $140K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.8% | 1,131 | $140K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 8,042 | $132K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 2,360 | $122K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 2,574 | $113K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 10,037 | $105K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,493 | $100K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.2% | 7,305 | $99K |
| 99284 | Emergency room visit (serious) | 1.2% | 3,806 | $99K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 6,252 | $97K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,585 | $90K |
| 80306 | 1.1% | 5,116 | $84K | |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 5,067 | $80K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,658 | $71K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,638 | $70K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,686 | $67K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 2,627 | $62K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,864 | $59K |
| 84703 | <1% | 6,570 | $59K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,058 | $58K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,428 | $56K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,654 | $56K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,917 | $52K |
| 97161 | <1% | 782 | $51K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,203 | $50K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,895 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,238 | $49K |
| 83880 | <1% | 2,311 | $46K | |
| 86901 | <1% | 2,501 | $42K | |
| 80061 | Lipid panel | <1% | 4,486 | $41K |
| 97162 | <1% | 421 | $40K | |
| 84484 | <1% | 4,966 | $37K | |
| 81000 | <1% | 11,698 | $36K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,752 | $34K |
| 83690 | <1% | 4,912 | $34K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,710 | $31K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,035 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 702 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 188 | $27K |
| 80320 | <1% | 1,777 | $27K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 524 | $26K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,692 | $25K |
| 86850 | <1% | 4,317 | $24K | |
| 74018 | <1% | 1,304 | $22K | |
| 87040 | <1% | 1,622 | $22K | |
| 83735 | <1% | 4,210 | $22K | |
| 73630 | <1% | 940 | $21K | |
| 87420 | <1% | 1,927 | $21K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 146 | $20K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,289 | $20K |
| 80329 | <1% | 1,500 | $20K | |
| 85027 | <1% | 4,028 | $20K | |
| 82565 | <1% | 1,793 | $19K | |
| 73610 | <1% | 1,187 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,078 | $19K |
| 97001 | <1% | 394 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,485 | $18K |
| 87077 | <1% | 2,293 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,107 | $16K |
| 99285 | Emergency room visit (most serious) | <1% | 974 | $16K |
| 87186 | <1% | 3,103 | $16K | |
| 80081 | <1% | 161 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,183 | $15K |
| 73130 | <1% | 667 | $15K | |
| 72141 | <1% | 41 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 922 | $13K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 560 | $13K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,928 | $13K |
| 73221 | <1% | 44 | $12K | |
| 87070 | <1% | 1,235 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $12K |
| 81003 | <1% | 4,567 | $11K | |
| 76830 | Ultrasound, transvaginal | <1% | 217 | $11K |
| 73110 | <1% | 470 | $10K | |
| 73562 | <1% | 366 | $10K | |
| 82948 | <1% | 2,244 | $10K | |
| 83605 | <1% | 936 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 93 | $9K |
| 86140 | <1% | 1,632 | $9K | |
| 84702 | <1% | 853 | $9K | |
| 86803 | <1% | 557 | $9K | |
| 87341 | <1% | 624 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,027 | $8K |
| 82607 | <1% | 543 | $8K | |
| 85610 | <1% | 2,740 | $8K | |
| 73030 | <1% | 388 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,744 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,066 | $7K |
| 85730 | <1% | 1,635 | $7K | |
| 90715 | <1% | 405 | $7K | |
| 86900 | <1% | 2,664 | $6K | |
| 82728 | <1% | 498 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 206 | $6K |
| 85379 | <1% | 560 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 43 | $5K |
| 76813 | <1% | 89 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 512 | $5K |
| 87081 | <1% | 610 | $5K | |
| 87340 | <1% | 1,040 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 260 | $5K |
| 88304 | <1% | 301 | $5K | |
| 84439 | <1% | 406 | $5K | |
| 72131 | <1% | 44 | $4K | |
| 82947 | <1% | 1,072 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 884 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,850 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 284 | $4K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 93 | $4K |
| 72100 | <1% | 211 | $3K | |
| 83540 | <1% | 564 | $3K | |
| 87088 | <1% | 424 | $3K | |
| 86762 | <1% | 524 | $3K | |
| A9270 | Non-covered item or service | <1% | 4,574 | $3K |
| 82570 | <1% | 701 | $3K | |
| 86592 | <1% | 992 | $3K | |
| 73502 | <1% | 161 | $2K | |
| 80076 | <1% | 524 | $2K | |
| 87075 | <1% | 305 | $2K | |
| 93971 | <1% | 67 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 911 | $2K |
| 81001 | <1% | 557 | $2K | |
| 85652 | <1% | 880 | $2K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 84 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 162 | $1K |
| 83655 | <1% | 104 | $1K | |
| 84112 | <1% | 20 | $1K | |
| 73090 | <1% | 84 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,047 | $1K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,902 | $1K |
| 95886 | <1% | 22 | $1K | |
| 88300 | <1% | 122 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,350 | $1K |
| 82803 | <1% | 104 | $997.87 | |
| 73560 | <1% | 86 | $940.35 | |
| 76642 | <1% | 57 | $915.21 | |
| 96376 | <1% | 504 | $899.77 | |
| 73590 | <1% | 54 | $895.98 | |
| 73080 | <1% | 51 | $876.15 | |
| 97032 | <1% | 355 | $861.30 | |
| 92523 | <1% | 20 | $833.88 | |
| 86705 | <1% | 68 | $820.31 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,749 | $775.06 |
| 83550 | <1% | 113 | $722.61 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,590 | $641.63 |
| 85007 | <1% | 573 | $609.11 | |
| 95911 | <1% | 12 | $522.19 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 611 | $492.51 |
| 86317 | <1% | 29 | $486.36 | |
| 85014 | <1% | 169 | $480.15 | |
| 87209 | <1% | 27 | $467.10 | |
| 85018 | <1% | 167 | $460.24 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 759 | $454.11 |
| 84156 | <1% | 98 | $405.56 | |
| 87045 | <1% | 48 | $350.22 | |
| 82550 | <1% | 49 | $319.39 | |
| 82553 | <1% | 27 | $275.54 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 286 | $255.15 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 414 | $246.40 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 783 | $220.58 |
| 87324 | <1% | 32 | $218.79 | |
| 87177 | <1% | 27 | $213.47 | |
| 87427 | <1% | 30 | $205.92 | |
| 83874 | <1% | 15 | $172.50 | |
| 81015 | <1% | 1,349 | $167.85 | |
| 87210 | <1% | 41 | $164.70 | |
| 87449 | <1% | 13 | $128.70 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 283 | $127.02 |
| 88720 | <1% | 120 | $109.95 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 223 | $90.52 |
| 84460 | <1% | 13 | $86.56 | |
| 87450 | <1% | 31 | $85.15 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 96 | $65.10 |
| 84153 | <1% | 14 | $52.54 | |
| 83615 | <1% | 19 | $51.78 | |
| 82043 | <1% | 12 | $49.62 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 63 | $45.92 |
| 84550 | <1% | 27 | $45.22 | |
| 82272 | <1% | 24 | $37.52 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 33 | $23.70 |
| 96523 | <1% | 42 | $11.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 51 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 18 | $0.00 |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 16 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 17 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 14 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 60 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, ANDREA (VP FINANCE/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.